Company: MBIO
Filing Date: 2025-04-01
Form Type: 424B3
Source: 0001104659-25-030657
Chunk: 8

Company: MUSTANG BIO, INC.
Filing Date: 2025-04-01
Form: 424B3
Chunk 8
---
​

General Risks and Risks Associated with Ownership of Our Common Stock

| ● | We may become involved in securities class action litigation that could divert management’s attention and harm our business. |

| ● | The market price for our common stock has been volatile and may continue to fluctuate or may decline significantly in the future. |

| ● | The occurrence of a catastrophic disaster could damage our facilities beyond insurance limits, or we could lose key data which could cause us to curtail or cease operations. |

| ● | We rely on information technology, and any internet or internal computer system failures, inadequacies, interruptions or compromises of our systems or the security of confidential information could damage our reputation and harm our business. |

| ● | Our employees, consultants, or third-party partners may engage in misconduct or other improper activities, including but not necessarily limited to noncompliance with regulatory standards and requirements or internal procedures, policies or agreements to which such employees, consultants and partners are subject, any of which could have a material adverse effect on our business. |

| ● | We may not be able to manage our business effectively if we are unable to attract and retain key personnel. |

| ● | Our growth is subject to economic and geopolitical conditions. |

| ● | Our business could be adversely affected by the effects of health pandemics or epidemics, which could cause significant disruptions in our operations. |

| ● | Our business and operations would suffer in the event of computer system failures, cyber-attacks, or deficiencies in our or third parties’ cybersecurity. |

​

<div align='center'>5</div>

​

Table of Contents

PART I

Item 1. Business

​

OVERVIEW

Mustang Bio, Inc. (“Mustang,”
“we,” “us,” “our” or the “Company”) is a clinical-stage biopharmaceutical company focused
on translating today’s medical breakthroughs into potential cures for difficult-to-treat cancers and autoimmune diseases. We aim
to acquire rights to these technologies by licensing or otherwise acquiring an ownership interest in the technologies, funding their research
and development and eventually either out-licensing or bringing the technologies to market.

Our pipeline is currently focused in two core
areas: CAR T therapies for autoimmune diseases and hematologic malignancies and CAR T therapies for solid tumors. For these therapies
we have partnered with world class research institutions, including the City of Hope National Medical Center (“COH” or “City
of Hope”), Fred Hutchinson Cancer Center (“Fred Hutch”), and Nationwide